Pharmacokinetics and pharmacodynamics of Hedgehog pathway inhibitors used in the treatment of advanced or treatment-refractory basal cell carcinoma

References

• Asgari MM, Moffet HH, Ray GT, et al. Trends in basal cell carcinoma incidence and identification of high-risk subgroups, 1998-2012. JAMA Dermatol. 2015;151(9):976–981. doi: 10.1001/jamadermatol.2015.1188
   PubMed Web of Science ®Google Scholar
• Leiter U, Eigentler T, Garbe C. Epidemiology of skin cancer. Adv Exp Med Biol. 2014;810:120–140.
   PubMedGoogle Scholar
• Bichakjian C, Armstrong A, Baum C, et al. Guidelines of care for the management of basal cell carcinoma. J Am Acad Dermatol. 2018;78(3):540–559. doi: 10.1016/j.jaad.2017.10.006
   PubMed Web of Science ®Google Scholar
• Peris K, Fargnoli MC, Garbe C, et al. Diagnosis and treatment of basal cell carcinoma: European consensus-based interdisciplinary guidelines. Eur J Cancer. 2019;118:10–34. doi: 10.1016/j.ejca.2019.06.003
   PubMed Web of Science ®Google Scholar
• NCCN Clinical Practice Guidelines® in oncology: basal cell skin cancer. Version. 2023;1(2023). Available at: https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1416
   Google Scholar
• Doan HQ, Chen L, Nawas Z, et al. Switching Hedgehog inhibitors and other strategies to address resistance when treating advanced basal cell carcinoma. Oncotarget. 2021;12(20):2089–2100. doi: 10.18632/oncotarget.28080
   PubMedGoogle Scholar
• Lear JT, Corner C, Dziewulski P, et al. Challenges and new horizons in the management of advanced basal cell carcinoma: a UK perspective. Br J Cancer. 2014;111(8):1476–1481. doi: 10.1038/bjc.2014.270
   PubMed Web of Science ®Google Scholar
• Lear JT, Dummer R, Guminski A. Using drug scheduling to manage adverse events associated with hedgehog pathway inhibitors for basal cell carcinoma. Oncotarget. 2021;12(26):2531–2540. doi: 10.18632/oncotarget.28145
   PubMedGoogle Scholar
• Epstein EH. Basal cell carcinomas: attack of the hedgehog. Nat Rev Cancer. 2008;8(10):743–754. doi: 10.1038/nrc2503
   PubMed Web of Science ®Google Scholar
• Varjosalo M, Taipale J. Hedgehog: functions and mechanisms. Genes Dev. 2008;22(18):2454–2472. doi: 10.1101/gad.1693608
   PubMed Web of Science ®Google Scholar
• Hahn H, Wicking C, Zaphiropoulous PG, et al. Mutations of the human homolog of drosophila patched in the nevoid basal cell carcinoma syndrome. Cell. 1996;85(6):841–851. doi: 10.1016/S0092-8674(00)81268-4
   PubMed Web of Science ®Google Scholar
• Johnson RL, Rothman AL, Xie J, et al. Human homolog of patched, a candidate gene for the basal cell nevus syndrome. Science. 1996;272(5268):1668–1671. doi: 10.1126/science.272.5268.1668
   PubMed Web of Science ®Google Scholar
• Gailani MR, Stahle-Backdahl M, Leffell DJ, et al. The role of the human homologue of drosophila patched in sporadic basal cell carcinomas. Nat Genet. 1996;14(1):78–81. doi: 10.1038/ng0996-78
   PubMed Web of Science ®Google Scholar
• Trieu KG, Tsai SY, Eberl M, et al. Basal cell carcinomas acquire secondary mutations to overcome dormancy and progress from microscopic to macroscopic disease. Cell Rep. 2022;39(5):110779. doi: 10.1016/j.celrep.2022.110779
   PubMed Web of Science ®Google Scholar
• Pellegrini C, Maturo MG, Di Nardo L, et al. Understanding the molecular genetics of basal cell carcinoma. Int J Mol Sci. 2017;18(11):2485. doi: 10.3390/ijms18112485
   PubMed Web of Science ®Google Scholar
• Xie J, Murone M, Luoh SM, et al. Activating smoothened mutations in sporadic basal-cell carcinoma. Nature. 1998;391(6662):90–92. doi: 10.1038/34201
   PubMed Web of Science ®Google Scholar
• Dahmane N, Lee J, Robins P, et al. Activation of the transcription factor Gli1 and the Sonic hedgehog signalling pathway in skin tumours. Nature. 1997;389(6653):876–881. doi: 10.1038/39918
   PubMed Web of Science ®Google Scholar
• Hutchin ME, Kariapper MS, Grachtchouk M, et al. Sustained Hedgehog signaling is required for basal cell carcinoma proliferation and survival: conditional skin tumorigenesis recapitulates the hair growth cycle. Genes Dev. 2005;19(2):214–223. doi: 10.1101/gad.1258705
   PubMed Web of Science ®Google Scholar
• Niewiadomski P, Niedziolka SM, Markiewicz L, et al. Gli proteins: regulation in development and cancer. Cells. 2019;8(2):147. doi: 10.3390/cells8020147
   PubMed Web of Science ®Google Scholar
• Kogerman P, Grimm T, Kogerman L, et al. Mammalian suppressor-of-fused modulates nuclear-cytoplasmic shuttling of gli-1. Nat Cell Biol. 1999;1(5):312–319. doi: 10.1038/13031
   PubMed Web of Science ®Google Scholar
• Gutzmer R, Solomon JA. Hedgehog pathway inhibition for the treatment of basal cell carcinoma. Target Oncol. 2019;14(3):253–267. doi: 10.1007/s11523-019-00648-2
   PubMed Web of Science ®Google Scholar
• Maun HR, Wen X, Lingel A, et al. Hedgehog pathway antagonist 5E1 binds hedgehog at the pseudo-active site. J Biol Chem. 2010;285(34):26570–26580. doi: 10.1074/jbc.M110.112284
   PubMed Web of Science ®Google Scholar
• Stanton BZ, Peng LF, Maloof N, et al. A small molecule that binds Hedgehog and blocks its signaling in human cells. Nat Chem Biol. 2009;5(3):154–156. doi: 10.1038/nchembio.142
   PubMed Web of Science ®Google Scholar
• Bosanac I, Maun HR, Scales SJ, et al. The structure of SHH in complex with HHIP reveals a recognition role for the shh pseudo active site in signaling. Nat Struct Mol Biol. 2009;16(7):691–697. doi: 10.1038/nsmb.1632
   PubMed Web of Science ®Google Scholar
• Yun T, Wang J, Yang J, et al. Discovery of small molecule inhibitors targeting the sonic Hedgehog. Front Chem. 2020;8:498. doi: 10.3389/fchem.2020.00498
   PubMed Web of Science ®Google Scholar
• Petrova E, Rios-Esteves J, Ouerfelli O, et al. Inhibitors of Hedgehog acyltransferase block sonic Hedgehog signaling. Nat Chem Biol. 2013;9(4):247–249. doi: 10.1038/nchembio.1184
   PubMed Web of Science ®Google Scholar
• Lauth M, Bergstrom A, Shimokawa T, et al. Inhibition of GLI-mediated transcription and tumor cell growth by small-molecule antagonists. Proc Natl Acad Sci U S A. 2007;104(20):8455–8460. doi: 10.1073/pnas.0609699104
   PubMed Web of Science ®Google Scholar
• Beauchamp EM, Ringer L, Bulut G, et al. Arsenic trioxide inhibits human cancer cell growth and tumor development in mice by blocking Hedgehog/GLI pathway. J Clin Invest. 2011;121(1):148–160. doi: 10.1172/JCI42874
   PubMed Web of Science ®Google Scholar
• Kim J, Lee JJ, Kim J, et al. Arsenic antagonizes the Hedgehog pathway by preventing ciliary accumulation and reducing stability of the Gli2 transcriptional effector. Proc Natl Acad Sci U S A. 2010;107(30):13432–13437. doi: 10.1073/pnas.1006822107
   PubMed Web of Science ®Google Scholar
• Berman DM, Karhadkar SS, Hallahan AR, et al. Medulloblastoma growth inhibition by hedgehog pathway blockade. Science. 2002;297(5586):1559–1561. doi: 10.1126/science.1073733
   PubMed Web of Science ®Google Scholar
• Chen JK, Taipale J, Cooper MK, et al. Inhibition of Hedgehog signaling by direct binding of cyclopamine to smoothened. Genes Dev. 2002;16(21):2743–2748. doi: 10.1101/gad.1025302
   PubMed Web of Science ®Google Scholar
• Sanchez P, Ruiz i Altaba A. In vivo inhibition of endogenous brain tumors through systemic interference of Hedgehog signaling in mice. Mech Dev. 2005;122(2):223–230. doi: 10.1016/j.mod.2004.10.002
   PubMed Web of Science ®Google Scholar
• Nguyen NM, Cho J. Hedgehog pathway inhibitors as targeted cancer therapy and strategies to overcome drug resistance. Int J Mol Sci. 2022;23(3):1733. doi: 10.3390/ijms23031733
   PubMed Web of Science ®Google Scholar
• Winkler JD, Isaacs A, Holderbaum L, et al. Design and synthesis of inhibitors of Hedgehog signaling based on the alkaloid cyclopamine. Org Lett. 2009;11(13):2824–2827. doi: 10.1021/ol900974u
   PubMed Web of Science ®Google Scholar
• Gould SE, Low JA, Marsters JC Jr., et al. Discovery and preclinical development of vismodegib. Expert Opin Drug Discov. 2014;9(8):969–984. doi: 10.1517/17460441.2014.920816
   PubMed Web of Science ®Google Scholar
• Cooper MK, Porter JA, Young KE, et al. Teratogen-mediated inhibition of target tissue response to Shh signaling. Science. 1998;280(5369):1603–1607. doi: 10.1126/science.280.5369.1603
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Assessment report for ODOMZO. London (UK): European Medicines Agency; 2015.
   Google Scholar
• European Medicines Agency. Assessment report for Erivedge. London (UK): European Medicines Agency; 2016.
   Google Scholar
• Axelson M, Liu K, Jiang X, et al. US Food and Drug Administration approval: vismodegib for recurrent, locally advanced, or metastatic basal cell carcinoma. Clin Cancer Res. 2013;19(9):2289–2293. doi: 10.1158/1078-0432.CCR-12-1956
   PubMed Web of Science ®Google Scholar
• Casey D, Demko S, Shord S, et al. FDA approval summary: sonidegib for locally advanced basal cell carcinoma. Clin Cancer Res. 2017;23(10):2377–2381. doi: 10.1158/1078-0432.CCR-16-2051
   PubMed Web of Science ®Google Scholar
• Erivedge® (vismodegib capsules) Prescribing Information (2023). Available at: https://www.gene.com/download/pdf/erivedge_prescribing.pdf
   Google Scholar
• ODOMZO® (sonidegib capsules) Prescribing Information (2022). Available at: https://www.odomzo.com/themes/custom/odomzo/global/pdfs/pi.pdf
   Google Scholar
• Migden MR, Guminski A, Gutzmer R, et al. Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial. Lancet Oncol. 2015;16(6):716–728. doi: 10.1016/S1470-2045(15)70100-2
   PubMed Web of Science ®Google Scholar
• Sekulic A, Migden MR, Oro AE, et al. Efficacy and safety of vismodegib in advanced basal-cell carcinoma. N Engl J Med. 2012;366(23):2171–2179. doi: 10.1056/NEJMoa1113713
   PubMed Web of Science ®Google Scholar
• Dummer R, Guminksi A, Gutzmer R, et al. Long-term efficacy and safety of sonidegib in patients with advanced basal cell carcinoma: 42-month analysis of the phase II randomized, double-blind BOLT study. Br J Dermatol. 2020;182(6):1369–1378. doi: 10.1111/bjd.18552
   PubMed Web of Science ®Google Scholar
• Sekulic A, Migden MR, Basset-Seguin N, et al. Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study. BMC Cancer. 2017;17(1):332. doi: 10.1186/s12885-017-3286-5
   PubMedGoogle Scholar
• Ding X, Chou B, Graham RA, et al. Determination of GDC-0449, a small-molecule inhibitor of the Hedgehog signaling pathway, in human plasma by solid phase extraction-liquid chromatographic-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2010;878(9–10):785–790. doi: 10.1016/j.jchromb.2010.01.039
   PubMed Web of Science ®Google Scholar
• Graham RA, Hop CE, Borin MT, et al. Single and multiple dose intravenous and oral pharmacokinetics of the hedgehog pathway inhibitor vismodegib in healthy female subjects. Br J Clin Pharmacol. 2012;74(5):788–796. doi: 10.1111/j.1365-2125.2012.04281.x
   PubMed Web of Science ®Google Scholar
• Graham RA, Lum BL, Morrison G, et al. A single dose mass balance study of the Hedgehog pathway inhibitor vismodegib (GDC-0449) in humans using accelerator mass spectrometry. Drug Metab Dispos. 2011;39(8):1460–1467. doi: 10.1124/dmd.111.039339
   PubMed Web of Science ®Google Scholar
• Zollinger M, Lozac’h F, Hurh E, et al. Absorption, distribution, metabolism, and excretion (ADME) of (1)(4)C-sonidegib (LDE225) in healthy volunteers. Cancer Chemother Pharmacol. 2014;74(1):63–75. doi: 10.1007/s00280-014-2468-y
   PubMed Web of Science ®Google Scholar
• Abou-Alfa GK, Lewis LD, LoRusso P, et al. Pharmacokinetics and safety of vismodegib in patients with advanced solid malignancies and hepatic impairment. Cancer Chemother Pharmacol. 2017;80(1):29–36. doi: 10.1007/s00280-017-3315-8
   PubMed Web of Science ®Google Scholar
• Graham RA, Lum BL, Cheeti S, et al. Pharmacokinetics of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with locally advanced or metastatic solid tumors: the role of alpha-1-acid glycoprotein binding. Clin Cancer Res. 2011;17(8):2512–2520. doi: 10.1158/1078-0432.CCR-10-2736
   PubMed Web of Science ®Google Scholar
• Lorusso PM, Jimeno A, Dy G, et al. Pharmacokinetic dose-scheduling study of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with locally advanced or metastatic solid tumors. Clin Cancer Res. 2011;17(17):5774–5782. doi: 10.1158/1078-0432.CCR-11-0972
   PubMed Web of Science ®Google Scholar
• Rodon J, Tawbi HA, Thomas AL, et al. A phase I, multicenter, open-label, first-in-human, dose-escalation study of the oral smoothened inhibitor sonidegib (LDE225) in patients with advanced solid tumors. Clin Cancer Res. 2014;20(7):1900–1909. doi: 10.1158/1078-0432.CCR-13-1710
   PubMed Web of Science ®Google Scholar
• Sharma MR, Karrison TG, Kell B, et al. Evaluation of food effect on pharmacokinetics of vismodegib in advanced solid tumor patients. Clin Cancer Res. 2013;19(11):3059–3067. doi: 10.1158/1078-0432.CCR-12-3829
   PubMed Web of Science ®Google Scholar
• Zhou J, Quinlan M, Hurh E, et al. Exposure-response analysis of sonidegib (LDE225), an oral inhibitor of the Hedgehog signaling pathway, for effectiveness and safety in patients with advanced solid tumors. J Clin Pharmacol. 2016;56(11):1406–1415. doi: 10.1002/jcph.749
   PubMed Web of Science ®Google Scholar
• Basset-Seguin N, Hauschild A, Kunstfeld R, et al. Vismodegib in patients with advanced basal cell carcinoma: primary analysis of STEVIE, an international, open-label trial. Eur J Cancer. 2017;86:334–348. doi: 10.1016/j.ejca.2017.08.022
   PubMed Web of Science ®Google Scholar
• Dreno B, Kunstfeld R, Hauschild A, et al. Two intermittent vismodegib dosing regimens in patients with multiple basal-cell carcinomas (MIKIE): a randomised, regimen-controlled, double-blind, phase 2 trial. Lancet Oncol. 2017;18(3):404–412. doi: 10.1016/S1470-2045(17)30072-4
   PubMed Web of Science ®Google Scholar
• Einolf HJ, Zhou J, Won C, et al. A physiologically-based pharmacokinetic modeling approach to predict drug-drug interactions of sonidegib (LDE225) with perpetrators of CYP3A in cancer patients. Drug Metab Dispos. 2017;45(4):361–374. doi: 10.1124/dmd.116.073585
   PubMed Web of Science ®Google Scholar
• Pan S, Wu X, Jiang J, et al. Discovery of NVP-LDE225, a potent and selective smoothened antagonist. ACS Med Chem Lett. 2010;1(3):130–134. doi: 10.1021/ml1000307
   PubMed Web of Science ®Google Scholar
• Giannetti AM, Wong H, Dijkgraaf GJ, et al. Identification, characterization, and implications of species-dependent plasma protein binding for the oral Hedgehog pathway inhibitor vismodegib (GDC-0449). J Med Chem. 2011;54(8):2592–2601. doi: 10.1021/jm1008924
   PubMed Web of Science ®Google Scholar
• Campione E, Di Prete M, Lozzi F, et al. High-risk recurrence basal cell carcinoma: focus on Hedgehog pathway inhibitors and review of the literature. Chemotherapy. 2020;65(1–2):2–10. doi: 10.1159/000509156
   PubMed Web of Science ®Google Scholar
• Goel V, Hurh E, Stein A, et al. Population pharmacokinetics of sonidegib (LDE225), an oral inhibitor of hedgehog pathway signaling, in healthy subjects and in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2016;77(4):745–755. doi: 10.1007/s00280-016-2982-1
   PubMed Web of Science ®Google Scholar
• Pooler DB, Ness DB, Sarantopoulos J, et al. The effect of sonidegib (LDE225) on the pharmacokinetics of bupropion and warfarin in patients with advanced solid tumours. Br J Clin Pharmacol. 2021;87(3):1291–1302. doi: 10.1111/bcp.14508
   PubMed Web of Science ®Google Scholar
• Malhi V, Colburn D, Williams SJ, et al. A clinical drug-drug interaction study to evaluate the effect of a proton-pump inhibitor, a combined P-glycoprotein/cytochrome 450 enzyme (CYP)3A4 inhibitor, and a CYP2C9 inhibitor on the pharmacokinetics of vismodegib. Cancer Chemother Pharmacol. 2016;78(1):41–49. doi: 10.1007/s00280-016-3020-z
   PubMed Web of Science ®Google Scholar
• Wong H, Chen JZ, Chou B, et al. Preclinical assessment of the absorption, distribution, metabolism and excretion of GDC-0449 (2-chloro-N-(4-chloro-3-(pyridin-2-yl)phenyl)-4-(methylsulfonyl)benzamide), an orally bioavailable systemic Hedgehog signalling pathway inhibitor. Xenobiotica. 2009;39(11):850–861. doi: 10.3109/00498250903180289
   PubMed Web of Science ®Google Scholar
• LoRusso PM, Piha-Paul SA, Mita M, et al. Co-administration of vismodegib with rosiglitazone or combined oral contraceptive in patients with locally advanced or metastatic solid tumors: a pharmacokinetic assessment of drug-drug interaction potential. Cancer Chemother Pharmacol. 2013;71(1):193–202. doi: 10.1007/s00280-012-1996-6
   PubMed Web of Science ®Google Scholar
• Lu T, Wang B, Gao Y, et al. Semi-mechanism-based population pharmacokinetic modeling of the Hedgehog pathway inhibitor vismodegib. CPT Pharmacometrics Syst Pharmacol. 2015;4(11):680–689. doi: 10.1002/psp4.12039
   PubMedGoogle Scholar
• Villani A, Fabbrocini G, Costa C, et al. Sonidegib: safety and efficacy in treatment of advanced basal cell carcinoma. Dermatol Ther. 2020;10(3):401–412. doi: 10.1007/s13555-020-00378-8
   PubMed Web of Science ®Google Scholar
• Jain S, Song R, Xie J. Sonidegib: mechanism of action, pharmacology, and clinical utility for advanced basal cell carcinomas. Onco Targets Ther. 2017;10:1645–1653. doi: 10.2147/OTT.S130910
   PubMed Web of Science ®Google Scholar
• Cancer Care Ontario. Drug monograph: Vismodegib (2019). Available at: https://www.cancercareontario.ca/en/drugformulary/drugs/vismodegib
   Google Scholar
• Dummer R, Ascierto PA, Basset-Seguin N, et al. Sonidegib and vismodegib in the treatment of patients with locally advanced basal cell carcinoma: a joint expert opinion. J Eur Acad Dermatol Venereol. 2020;34(9):1944–1956. doi: 10.1111/jdv.16230
   PubMed Web of Science ®Google Scholar
• Horsmans Y, Zhou J, Liudmila M, et al. Effects of mild to severe hepatic impairment on the pharmacokinetics of sonidegib: a multicenter, open-label, parallel-group study. Clin Pharmacokinet. 2018;57(3):345–354. doi: 10.1007/s40262-017-0560-2
   PubMed Web of Science ®Google Scholar
• Ventarola DJ, Silverstein DI. Vismodegib-associated hepatotoxicity: a potential side effect detected in postmarketing surveillance. J Am Acad Dermatol. 2014;71(2):397–398. doi: 10.1016/j.jaad.2014.04.023
   PubMed Web of Science ®Google Scholar
• Edwards BJ, Raisch DW, Saraykar SS, et al. Hepatotoxicity with vismodegib: an MD Anderson Cancer center and research on adverse drug events and reports project. Drugs R D. 2017;17(1):211–218. doi: 10.1007/s40268-016-0168-2
   PubMed Web of Science ®Google Scholar
• Atwood SX, Sarin KY, Whitson RJ, et al. Smoothened variants explain the majority of drug resistance in basal cell carcinoma. Cancer Cell. 2015;27(3):342–353. doi: 10.1016/j.ccell.2015.02.002
   PubMed Web of Science ®Google Scholar
• Shimizu Y, Ishii T, Ogawa K, et al. Biochemical characterization of smoothened receptor antagonists by binding kinetics against drug-resistant mutant. Eur J Pharmacol. 2015;764:220–227. doi: 10.1016/j.ejphar.2015.05.062
   PubMed Web of Science ®Google Scholar
• Sharpe HJ, Pau G, Dijkgraaf GJ, et al. Genomic analysis of smoothened inhibitor resistance in basal cell carcinoma. Cancer Cell. 2015;27(3):327–341. doi: 10.1016/j.ccell.2015.02.001
   PubMed Web of Science ®Google Scholar
• Pricl S, Cortelazzi B, Dal Col V, et al. Smoothened (SMO) receptor mutations dictate resistance to vismodegib in basal cell carcinoma. Mol Oncol. 2015;9(2):389–397. doi: 10.1016/j.molonc.2014.09.003
   PubMed Web of Science ®Google Scholar
• Danial C, Sarin KY, Oro AE, et al. An investigator-initiated open-label trial of sonidegib in advanced basal cell carcinoma patients resistant to vismodegib. Clin Cancer Res. 2016;22(6):1325–1329. doi: 10.1158/1078-0432.CCR-15-1588
   PubMed Web of Science ®Google Scholar
• Heppt MV, Gebhardt C, Hassel JC, et al. Long-term management of advanced basal cell carcinoma: current challenges and future perspectives. Cancers (Basel). 2022;14(19):4547. doi: 10.3390/cancers14194547
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration. Oncology pharmaceuticals: reproductive toxicity testing and labeling recommendations guidance for industry (2019). Available at: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/oncology-pharmaceuticals-reproductive-toxicity-testing-and-labeling-recommendations-guidance
   Google Scholar
• Gutzmer R, Loquai C, Robert C, et al. Key clinical adverse events in patients with advanced basal cell carcinoma treated with sonidegib or vismodegib: a Post Hoc analysis. Dermatol Ther. 2021;11(5):1839–1849. doi: 10.1007/s13555-021-00588-8
   Web of Science ®Google Scholar
• Grossmann LE, Ramelyte E, Nageli MC, et al. Eight years of real-life experience with smoothened inhibitors in a Swiss Tertiary skin Referral center. Cancers (Basel). 2022;14(10):2496. doi: 10.3390/cancers14102496
   PubMed Web of Science ®Google Scholar
• Ge W, Chen CI, Wu N, et al. Hedgehog pathway inhibitor real-world treatment patterns in patients with basal cell carcinoma: a claims-based analysis. Future Oncol. 2022;18(23):2561–2572. doi: 10.2217/fon-2022-0373
   PubMed Web of Science ®Google Scholar
• Mannino M, Piccerillo A, Fabbrocini G, et al. Clinical characteristics of an Italian patient population with advanced BCC and real-life evaluation of HHI safety and effectiveness. Dermatology. 2023;1–9. doi: 10.1159/000531280
   PubMed Web of Science ®Google Scholar
• Villani A, Potestio L, Fabbrocini G, et al. New emerging treatment options for advanced basal cell carcinoma and squamous cell carcinoma. Adv Ther. 2022;39(3):1164–1178. doi: 10.1007/s12325-022-02044-1
   PubMed Web of Science ®Google Scholar
• Jimeno A, Weiss GJ, Miller WH Jr., et al. Phase I study of the Hedgehog pathway inhibitor IPI-926 in adult patients with solid tumors. Clin Cancer Res. 2013;19(10):2766–2774. doi: 10.1158/1078-0432.CCR-12-3654
   PubMed Web of Science ®Google Scholar
• Trial of patidegib gel 2%, 4%, and vehicle to decrease the number of surgically eligible basal cell carcinomas in gorlin syndrome patients. Available at: https://clinicaltrials.gov/study/NCT02762084
   Google Scholar
• Clinical trial of patidegib gel 2%, 4%, and vehicle applied once or twice daily to decrease the GLI1 biomarker in sporadic nodular basal cell carcinomas (BCC). Available at: https://clinicaltrials.gov/study/NCT02828111
   Google Scholar
• Bendell J, Andre V, Ho A, et al. Phase I study of LY2940680, a Smo antagonist, in patients with advanced cancer including treatment-naive and previously treated basal cell carcinoma. Clin Cancer Res. 2018;24(9):2082–2091. doi: 10.1158/1078-0432.CCR-17-0723
   PubMed Web of Science ®Google Scholar
• Ueno H, Kondo S, Yoshikawa S, et al. A phase I and pharmacokinetic study of taladegib, a Smoothened inhibitor, in Japanese patients with advanced solid tumors. Invest New Drugs. 2018;36(4):647–656. doi: 10.1007/s10637-017-0544-y
   PubMed Web of Science ®Google Scholar
• Xie H, Paradise BD, Ma WW, et al. Recent advances in the clinical targeting of Hedgehog/GLI signaling in cancer. Cells. 2019;8(5):394. doi: 10.3390/cells8050394
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration. FDA approves first treatment for advanced form of the second most common skin cancer (2018). Available at: https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-advanced-form-second-most-common-skin-cancer
   Google Scholar
• LIBTAYO® (cemiplimab-rwlc) highlights of Prescribing information (2022). Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761097s014lbl.pdf
   Google Scholar
• Villani A, Ocampo-Garza SS, Potestio L, et al. Cemiplimab for the treatment of advanced cutaneous squamous cell carcinoma. Expert Opin Drug Saf. 2022;21(1):21–29. doi: 10.1080/14740338.2022.1993819
   PubMed Web of Science ®Google Scholar
• Falchook GS, Leidner R, Stankevich E, et al. Responses of metastatic basal cell and cutaneous squamous cell carcinomas to anti-PD1 monoclonal antibody REGN2810. J Immunother Cancer. 2016;4(1):70. doi: 10.1186/s40425-016-0176-3
   PubMed Web of Science ®Google Scholar
• Stratigos AJ, Sekulic A, Peris K, et al. Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: an open-label, multi-centre, single-arm, phase 2 trial. Lancet Oncol. 2021;22(6):848–857. doi: 10.1016/S1470-2045(21)00126-1
   PubMed Web of Science ®Google Scholar
• Bossi P, Ascierto PA, Basset-Seguin N, et al. Long-term strategies for management of advanced basal cell carcinoma with hedgehog inhibitors. Crit Rev Oncol Hematol. 2023;189:104066. doi: 10.1016/j.critrevonc.2023.104066
   PubMed Web of Science ®Google Scholar
• Wang J, Cui B, Li X, et al. The emerging roles of Hedgehog signaling in tumor immune microenvironment. Front Oncol. 2023;13:1171418. doi: 10.3389/fonc.2023.1171418
   PubMed Web of Science ®Google Scholar
• Giammona A, Crivaro E, Stecca B. Emerging roles of Hedgehog signaling in cancer immunity. Int J Mol Sci. 2023;24(2):1321. doi: 10.3390/ijms24021321
   PubMed Web of Science ®Google Scholar
• Gambini D, Passoni E, Nazzaro G, et al. Basal cell carcinoma and Hedgehog pathway inhibitors: focus on immune response. Front Med. 2022;9:893063. doi: 10.3389/fmed.2022.893063
   Web of Science ®Google Scholar
• Otsuka A, Dreier J, Cheng PF, et al. Hedgehog pathway inhibitors promote adaptive immune responses in basal cell carcinoma. Clin Cancer Res. 2015;21(6):1289–1297. doi: 10.1158/1078-0432.CCR-14-2110
   PubMed Web of Science ®Google Scholar